Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ekene Enemchukwu

Urogynecology and Reconstructive Pelvic Surgery Stanford, CA Medical Doctor

NPI 1750558193 CMS profile 1266984

300 Pasteur Dr, Stanford, CA 94305

Open in the dashboard

General payments

$15,004

52 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$19,537 paid to institutions, not to them · program years 2021–2023

Through program year 2025, Ekene Enemchukwu of Stanford, CA is reported in the CMS Open Payments database as having received $15,004 across 52 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $19,537 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 72nd percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $357 5
2024 General $367 7
2023 General $6,761 14
2022 General $6,037 18
2021 General $500 1
2020 General $117 1
2019 General $865 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ekene Enemchukwu
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Ekene Enemchukwu were reported at $357. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.

Show as a table
Year Ekene Enemchukwu Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $865 $799 $319–$2,013 $163
2020 $117 $384 $158–$1,360 $114
2021 $500 $641 $247–$2,515 $132
2022 $6,037 $843 $347–$2,794 $149
2023 $6,761 $819 $308–$2,302 $160
2024 $367 $882 $306–$2,459 $164
2025 $357 $779 $301–$2,705 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $7,324 16 payments
  2. AbbVie, Inc. $3,609 7 payments
  3. Urovant Sciences Inc $2,426 12 payments
  4. Medtronic USA, Inc. $982 7 payments
  5. Medtronic, Inc. $311 3 payments
  6. Bluewind Medical $173 2 payments
  7. Coloplast Corp $136 3 payments
  8. Axonics Modulation Technologies, Inc. $25 1 payment
  9. Ambu Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $7,950 5 payments
  2. Travel and Lodging $4,690 18 payments
  3. Food and Beverage $1,820 28 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $545 1 payment
Products named General payments · program years 2019–2025
  1. BOTOX Facial Aesthetics $3,342 4 payments
  2. GEMTESA $2,426 12 payments
  3. INTERSTIM Sacral Nerve Stimulation $982 7 payments
  4. GENERAL - FEMALE SUI $500 1 payment
  5. INTERSTIM Sacral Nerve Stimulation $311 3 payments
  6. REVI $173 2 payments
  7. BOTOX Botox Therapeutic $172 2 payments
  8. General - Therapies $143 1 payment
  9. Altis $136 3 payments
  10. Solyx SIS System $110 5 payments
  11. Other $120 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

91

Median for Urology: 1,053

Drug cost

$37,222

Median for Urology: $101,464

Branded share of claims

44%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 24 $23,728
Myrbetriq Mirabegron Brand 16 $11,404
Estradiol Generic 26 $1,827
Finasteride Generic 12 $198
Cephalexin Generic 13 $65

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$55,943

Medicare's payments for the services billed

Medicare patients

190

Average age 73

Services billed

403

144 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 49%
Osteoporosis 28%
Depression 27%
Diabetes 26%
Ischemic heart disease 21%
Cancer 21%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record